Approximately 700,000 people in the UK suffer with chronic migraines, which typically cause nausea and sensitivity to light and sound. To be classed as chronic migraines, a patient must have headaches on at least 15 days a month, 8 of which have to be migraines.
It is thought that the botox treatment, developed by Allergan, the global speciality pharmaceutical company, may be effective as it helps to block the pain signals and relaxes muscles.
Back in February 2012, NICE rejected the botox treatment as it did not see enough evidence to justify its approval. In a turnaround, NICE are now backing its use in those chronic migraine patients who has not been helped by the use of at least three previous medications. They are expected to issue final guidelines in June 2012.